ATE513550T1 - Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung - Google Patents

Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung

Info

Publication number
ATE513550T1
ATE513550T1 AT07023058T AT07023058T ATE513550T1 AT E513550 T1 ATE513550 T1 AT E513550T1 AT 07023058 T AT07023058 T AT 07023058T AT 07023058 T AT07023058 T AT 07023058T AT E513550 T1 ATE513550 T1 AT E513550T1
Authority
AT
Austria
Prior art keywords
treat
ibat inhibitor
constitution
prevent
prevent constitution
Prior art date
Application number
AT07023058T
Other languages
English (en)
Inventor
Hasse Roland Abrahamsson
Per-Goeran Gillberg
Original Assignee
Albireo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9956272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE513550(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Albireo Ab filed Critical Albireo Ab
Application granted granted Critical
Publication of ATE513550T1 publication Critical patent/ATE513550T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
AT07023058T 2003-04-05 2004-04-01 Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung ATE513550T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0307918.3A GB0307918D0 (en) 2003-04-05 2003-04-05 Therapeutic use

Publications (1)

Publication Number Publication Date
ATE513550T1 true ATE513550T1 (de) 2011-07-15

Family

ID=9956272

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04725081T ATE387194T1 (de) 2003-04-05 2004-04-01 Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
AT07023058T ATE513550T1 (de) 2003-04-05 2004-04-01 Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04725081T ATE387194T1 (de) 2003-04-05 2004-04-01 Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung

Country Status (33)

Country Link
US (1) US7514421B2 (de)
EP (2) EP1610770B1 (de)
JP (2) JP4870552B2 (de)
KR (1) KR101321577B1 (de)
CN (1) CN100366241C (de)
AR (1) AR043985A1 (de)
AT (2) ATE387194T1 (de)
AU (1) AU2004228731B2 (de)
BR (1) BRPI0408858A (de)
CA (1) CA2520109C (de)
CO (1) CO5640076A2 (de)
CY (2) CY1107424T1 (de)
DE (1) DE602004012079T2 (de)
DK (2) DK1894564T3 (de)
ES (2) ES2368350T3 (de)
GB (1) GB0307918D0 (de)
HK (1) HK1085666A1 (de)
IL (1) IL170913A (de)
IS (1) IS8113A (de)
MX (1) MXPA05010706A (de)
MY (1) MY137757A (de)
NO (1) NO335140B1 (de)
NZ (1) NZ542835A (de)
PL (2) PL1610770T3 (de)
PT (2) PT1894564E (de)
RU (2) RU2342928C2 (de)
SA (1) SA04250066B1 (de)
SI (2) SI1894564T1 (de)
TW (1) TWI338577B (de)
UA (1) UA84141C2 (de)
UY (1) UY28258A1 (de)
WO (1) WO2004089350A1 (de)
ZA (1) ZA200507996B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
JP3616635B2 (ja) 2001-09-08 2005-02-02 アストラゼネカ アクチボラグ 高脂質血症の治療のための回腸胆汁酸運搬（ｉｂａｔ）阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
AR057828A1 (es) * 2005-09-29 2007-12-19 Astrazeneca Ab Compuestos derivados de azetidina, su preparacion y composicion farmaceuutica
BRPI0808495A2 (pt) * 2007-03-08 2014-07-22 Albireo Ab Derivados de ácido 2-substituído-3-fenilpropiônico e seu uso no tratamento de doença inflamatória intestinal
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
EP2575821B1 (de) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Gallensäurerückflusshemmer und satiogene zur behandlung von diabetes, adipositas und entzündlichen magen-darm-erkrankungen
CN103260625B (zh) 2010-11-08 2016-01-06 阿尔比里奥公司 用于治疗肝脏疾病的ibat抑制剂
KR102051031B1 (ko) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
CA2853285C (en) 2011-10-28 2020-05-05 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2968230A2 (de) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Gallensäurerückflusshemmer zur behandlung von primär sklerosierender cholongitis und entzündlichen darmerkrankungen
KR20160003664A (ko) 2013-03-15 2016-01-11 루메나 파마수티컬즈, 인코포레이티드 바렛 식도 및 위식도 역류 질환 치료용 담즙산 재순환 억제제
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR101420315B1 (ko) 2014-03-19 2014-07-17 남봉길 약학적 액제 조성물
WO2015199146A1 (ja) * 2014-06-25 2015-12-30 味の素株式会社 固形製剤及びその安定化方法
KR102560954B1 (ko) 2014-06-25 2023-07-31 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (de) 2014-10-24 2016-04-27 Ferring BV Kristalline Form von elobixibat
WO2017031121A1 (en) 2015-08-17 2017-02-23 Liang Alfred Chi-Yeh Liquid formulations containing picosulfate and magnesium citrate
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
HUE063823T2 (hu) 2017-06-20 2024-02-28 Heterociklusos vegyület és annak alkalmazása a kolinerg muszkarin M1 receptor pozitív alloszterikus modulátoraként
EP3664781A1 (de) 2017-08-09 2020-06-17 Albireo AB Cholestyramingranulate, orale cholestyraminformulierungen und ihre verwendung
BR112020017353A2 (pt) 2018-03-09 2020-12-15 Elobix Ab Processos para a preparação de um composto e de uma modificação de cristal iv de elobixibat.
US10428109B1 (en) 2018-03-09 2019-10-01 Elobix Ab Process for the preparation of 1,5-benzothiazepine compounds
TW202015699A (zh) 2018-06-05 2020-05-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
MX2020013839A (es) 2018-06-20 2021-03-25 Albireo Ab Formulacion farmaceutica de odevixibat.
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
AU2020221834A1 (en) 2019-02-12 2021-09-02 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an ASBTI in patients with bile salt export pump deficiency
EP4069361B1 (de) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren
EP4069247A1 (de) 2019-12-04 2022-10-12 Albireo AB Benzothiadiazepinverbindungen und ihre verwendung als gallensäuremodulatoren
EP4069360B1 (de) 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepinverbindungen und ihre verwendung als gallensäuremodulatoren
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CN116157389A (zh) 2020-08-03 2023-05-23 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN116583504A (zh) 2020-12-04 2023-08-11 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
WO2022166680A1 (zh) * 2021-06-25 2022-08-11 苏州科睿思制药有限公司 奥德昔巴特的晶型及其制备方法和用途
WO2023203248A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8705837A1 (es) 1985-01-10 1987-05-16 Tanabe Seiyaku Co Un procedimiento para la preparacion de derivados de naftaleno.
JPS6310746A (ja) 1986-07-01 1988-01-18 Tanabe Seiyaku Co Ltd ナフタレン誘導体
US4900757A (en) 1988-12-08 1990-02-13 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
ES2096614T3 (es) 1990-12-06 1997-03-16 Hoechst Ag Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de este compuesto como medicamento.
EP0701991B1 (de) 1991-10-17 1999-01-20 Shionogi & Co., Ltd. Verfahren zum Herstellen von Lignin-Analoga und Ausgangsprodukte dafür
US5430116A (en) 1991-12-20 1995-07-04 Hoechst Aktiengesellschaft Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals
JPH05186357A (ja) * 1991-12-31 1993-07-27 Shigeo Ochi 飲食物消化分解産物吸収抑制手段
GEP20001968B (en) * 1992-01-21 2000-03-05 Glaxo Spa Arilthio Compounds as Antibacterial and Antiviral Agents
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
ES2111092T3 (es) 1992-06-12 1998-03-01 Hoechst Ag Derivados de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
ATE167662T1 (de) 1993-04-16 1998-07-15 Shionogi & Co Verfahren zur herstellung eines lignan-derivats
TW289021B (de) 1993-05-08 1996-10-21 Hoechst Ag
EP0624593A3 (de) 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289020B (de) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CA2199944A1 (en) 1994-09-13 1996-03-21 Len Fang Lee Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
GB9423172D0 (en) 1994-11-17 1995-01-04 Wellcom Foundation The Limited Hypolipidemic benzothiazepines
EP0888333B1 (de) 1996-03-11 2005-08-31 G.D. Searle LLC Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate-aufnahme
EP0929575A4 (de) 1996-08-23 2004-09-08 Human Genome Sciences Inc Neue menschliche wachstumsfaktoren.
JPH1072371A (ja) 1996-08-28 1998-03-17 Sankyo Co Ltd 回腸型胆汁酸トランスポーター阻害剤
GB9704208D0 (en) 1997-02-28 1997-04-16 Glaxo Group Ltd Chemical compounds
CA2283575A1 (en) 1997-03-11 1998-09-17 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
EP0864582B1 (de) 1997-03-14 2003-06-04 Aventis Pharma Deutschland GmbH Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
DE19845402B4 (de) 1998-10-02 2005-04-07 Aventis Pharma Deutschland Gmbh Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
ATE268758T1 (de) 1997-04-04 2004-06-15 Aventis Pharma Gmbh Hypolipidämische propanolaminderivate
AU7552198A (en) 1997-06-11 1998-12-30 Sankyo Company Limited Benzylamine derivatives
AUPO763197A0 (en) * 1997-06-30 1997-07-24 Sigma Pharmaceuticals Pty Ltd Health supplement
JP2001526284A (ja) 1997-12-19 2001-12-18 ジー・ディー・サール・アンド・カンパニー 鏡像異性体的に濃縮されたテトラヒドロベンゾチエピンオキシド類を製造する方法
GB9800428D0 (en) 1998-01-10 1998-03-04 Glaxo Group Ltd Chemical compounds
DE19825804C2 (de) 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
DE19845403B4 (de) 1998-10-02 2005-02-10 Aventis Pharma Deutschland Gmbh Mit Gallensäuren verknüpfte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845406C2 (de) 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AU1684400A (en) 1998-12-11 2000-07-03 Sankyo Company Limited Substituted benzylamines
BR9916565A (pt) 1998-12-23 2002-01-29 Searle Llc Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
MXPA01006471A (es) 1998-12-23 2004-03-10 Searle Llc Combinaciones de inhibidores de transporte de acido biliar ileal e inhibidores de proteina de transferencia de ester colesterilio cpara indicaciones cardiovasculares.
ES2189529T3 (es) 1998-12-23 2003-07-01 Searle Llc Combinaciones de inhiidores para el transporte de acidos biliares en el ileon y agentes complejantes para indicaciones cardiovasculares.
AU776952B2 (en) 1998-12-23 2004-09-30 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
JP2002533411A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための組み合わせ
HUP0105409A3 (en) 1999-02-12 2004-11-29 G D Searle Llc Chicago 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake, use thereof and pharmaceutical compositions containing them
DE19916108C1 (de) 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6287609B1 (en) * 1999-06-09 2001-09-11 Wisconsin Alumni Research Foundation Unfermented gel fraction from psyllium seed husks
CZ290178B6 (cs) 1999-07-22 2002-06-12 Sankyo Company Limited Deriváty cyklobutenu
WO2001034570A1 (fr) 1999-11-08 2001-05-17 Sankyo Company, Limited Derives heterocycliques azotes
WO2001060807A1 (en) 2000-02-18 2001-08-23 Merck & Co. Inc. Aryloxyacetic acids for diabetes and lipid disorders
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US20020061888A1 (en) 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
JP2003528830A (ja) 2000-03-10 2003-09-30 ファルマシア・コーポレーション テトラヒドロベンゾチエピン類の製造方法
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) * 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002053548A1 (en) 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Benzothiazepine derivatives
US6506921B1 (en) * 2001-06-29 2003-01-14 Virginia Tech Intellectual Properties, Inc. Amine compounds and curable compositions derived therefrom
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
JP3616635B2 (ja) * 2001-09-08 2005-02-02 アストラゼネカ アクチボラグ 高脂質血症の治療のための回腸胆汁酸運搬（ｉｂａｔ）阻害活性を持つベンゾチアゼピン及びベンゾチアジアゼピン誘導体
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0216321D0 (en) 2002-07-13 2002-08-21 Astrazeneca Ab Therapeutic treatment
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) * 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use

Also Published As

Publication number Publication date
MY137757A (en) 2009-03-31
JP2006522082A (ja) 2006-09-28
NO335140B1 (no) 2014-09-29
NZ542835A (en) 2009-01-31
CA2520109A1 (en) 2004-10-21
DK1610770T3 (da) 2008-05-13
NO20054369L (no) 2005-11-15
RU2005128792A (ru) 2006-05-10
ES2368350T3 (es) 2011-11-16
RU2482850C2 (ru) 2013-05-27
JP2011173925A (ja) 2011-09-08
CY1107424T1 (el) 2012-12-19
ZA200507996B (en) 2007-04-25
TW200505434A (en) 2005-02-16
PL1610770T3 (pl) 2008-07-31
ES2299832T3 (es) 2008-06-01
EP1610770B1 (de) 2008-02-27
EP1610770A1 (de) 2006-01-04
JP5421326B2 (ja) 2014-02-19
TWI338577B (en) 2011-03-11
HK1085666A1 (en) 2006-09-01
PT1610770E (pt) 2008-04-10
US7514421B2 (en) 2009-04-07
WO2004089350A1 (en) 2004-10-21
DE602004012079T2 (de) 2009-02-26
CY1111995T1 (el) 2015-11-04
EP1894564A2 (de) 2008-03-05
DK1894564T3 (da) 2011-08-29
US20060199797A1 (en) 2006-09-07
CN1771027A (zh) 2006-05-10
EP1894564A3 (de) 2009-09-09
PT1894564E (pt) 2011-07-26
CA2520109C (en) 2012-03-20
KR20050121241A (ko) 2005-12-26
NO20054369D0 (no) 2005-09-21
PL1894564T3 (pl) 2011-11-30
IL170913A (en) 2010-11-30
GB0307918D0 (en) 2003-05-14
AU2004228731B2 (en) 2008-02-28
KR101321577B1 (ko) 2013-10-25
MXPA05010706A (es) 2005-12-12
AR043985A1 (es) 2005-08-17
RU2008129204A (ru) 2010-01-27
EP1894564B1 (de) 2011-06-22
ATE387194T1 (de) 2008-03-15
CO5640076A2 (es) 2006-05-31
JP4870552B2 (ja) 2012-02-08
AU2004228731A1 (en) 2004-10-21
IS8113A (is) 2005-11-01
BRPI0408858A (pt) 2006-04-11
UY28258A1 (es) 2004-11-30
CN100366241C (zh) 2008-02-06
RU2342928C2 (ru) 2009-01-10
SA04250066B1 (ar) 2008-09-22
SI1610770T1 (sl) 2008-06-30
UA84141C2 (ru) 2008-09-25
DE602004012079D1 (de) 2008-04-10
SI1894564T1 (sl) 2011-08-31

Similar Documents

Publication Publication Date Title
ATE387194T1 (de) Verwendung eines ibat-hemmers zur behandlung oder vorbeugung von verstopfung
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
ATE428424T1 (de) 1-benzoyl-piperazin-derivate als glycin- aufnahmehemmer zur behandlung von psychosen
ATE374610T1 (de) 1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
DE602005006938D1 (de) Gebrauchslimitierendes elektronisches Schlüsselsystem für Plasmagerät zur Behandlung von Gewebeoberflächen
ATE524479T1 (de) Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
DE602006020201D1 (de) Aerobes-anaerobes Verfahren zur Behandlung von organisch belasteten Abwässern
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
ATE410169T1 (de) Verwendung eines phenothiazin-derivats zur prävention und/oder behandlung von gerhörverlust
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006021192D1 (de) Visnadin zur Behandlung von Kopfhautjucken
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE423099T1 (de) Zur behandlung von schmerzen geeignete piperazine
DE60331359D1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
ATE418337T1 (de) Verwendung von dihydroimidazolonen zur behandlung von epilepsie bei hunden
DE502007006880D1 (de) Verwendung von gallium (iii) komplexen zur behandlung von melanomen
DE602006018725D1 (de) Amidin-derivate zur verwendung in der vorbeugung oder behandlung von glaukom
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
DE60317661D1 (de) Annelierte pyrrol-verbindungen als protonenpumpenhemmer zur behandlung von geschwüren
ATE373477T1 (de) Cci-779 zur behandlung von mantelzelllymphom
DE602007003350D1 (de) Behandlung von polysilazan-abfall

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1894564

Country of ref document: EP